Related Experiment Video
Updated: Jun 17, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Economic opportunities and challenges for pharmacogenomics
Patricia A Deverka1, John Vernon, Howard L McLeod
1UNC Institute for Pharmacogenomics and Individualized Therapy, Department of Health Policy and Management, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA. pat_deverka@unc.edu
Annual Review of Pharmacology and Toxicology
|January 9, 2010
Summary
Economic evaluations in pharmacogenomics guide healthcare resource allocation. Demonstrating cost-effectiveness requires proving clinical effectiveness through comparative research and cost analysis.
Area of Science:
- Pharmacoeconomics
- Genomic Medicine
- Health Services Research
Background:
- Economic evaluation is crucial for healthcare resource allocation, comparing costs and benefits of interventions.
- Pharmacogenomics, using genetic information to optimize drug therapy, is anticipated to be cost-effective.
- Both the pharmaceutical industry and payers utilize economic analyses for investment and coverage decisions.
Purpose of the Study:
- To review the application of economic analyses in pharmacogenomics.
- To explore how pharmacogenomic testing can inform investment and coverage decisions.
- To identify factors necessary for demonstrating the economic benefits of pharmacogenomics.
Main Methods:
- Literature review of economic evaluations in pharmacogenomics.
- Analysis of pharmacogenomics' role in drug development and clinical practice.
- Discussion of requirements for proving cost-effectiveness.
Main Results:
- Economic analyses are applied by industry and payers in pharmacogenomics.
- Anticipation of cost-effectiveness for pharmacogenomic testing due to improved drug efficacy and reduced toxicity.
- Clinical effectiveness is a prerequisite for demonstrating economic benefits.
Conclusions:
- Pharmacogenomic testing's economic benefits depend on proven clinical effectiveness.
- Increased involvement of pharmacogenomics experts in comparative effectiveness research is needed.
- Integrating cost considerations is vital for determining the value of pharmacogenomic testing.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...